SCHEMBL6231710

SCHEMBL6231710

Nc1c2c(cc3c1CCC3)CCC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPK1 P28482 1/20 0.42
BPTF Q12830 1/20 0.42
NOS3 P29474 2/20 0.37
NOS1 P29475 2/20 0.37
NOS2 P35228 2/20 0.37
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
PKM P14618 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NLRP3 Q96P20 4/20 0.34
BCHE P06276 4/20 0.33
LMNA P02545 1/20 0.33
GRIN1 Q05586 3/20 0.32
GRIN2A Q12879 3/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19791796 0.97 ACHE (0.46) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL20681022 0.95 ACHE (0.39) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL30498486 0.95 ACHE (0.39) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL23808911 0.94 ACHE (0.44) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL25404714 0.87 ACHE (0.34) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL21810680 0.82 ACHE (0.31) ACHE
SCHEMBL23674334 0.80 MEN1 (0.31) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL22282173 0.80 MEN1 (0.31) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL23674373 0.80 MEN1 (0.31) ACHEMEN1KMT2AMAPK1BPTF
SCHEMBL20692058 0.80 MEN1 (0.31) ACHEMEN1KMT2AMAPK1BPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150291-A1 PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2024-05-09 US claimed
EP-4359385-A2 PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-05-01 EP claimed
EP-3867231-B1 NOVEL PROCESSES INFLAZOME LTD (IE) 2024-05-01 EP claimed
US-11724988-B2 Processes INFLAZOME LIMITED (IE) 2023-08-15 US claimed
WO-2022268935-A2 NOVEL PROCESS F. HOFFMANN-LA ROCHE AG (CH) 2022-12-29 WO claimed
US-20220064125-A1 NOVEL PROCESSES INFLAZOME LIMITED (IE) 2022-03-03 US claimed
WO-2020079207-A1 NOVEL PROCESSES INFLAZOME LIMITED (IE) 2020-04-23 WO claimed
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators GENENTECH, INC. (US) 2026-05-05 US disclosed
US-20250388568-A1 NLRP3 INHIBITORS KODIAK SCIENCES INC (US) 2025-12-25 US disclosed
US-12466800-B2 N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) ZOMAGEN BIOSCIENCES LTD (US) 2025-11-11 US disclosed
US-12459925-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NodThera Limited (GB) 2025-11-04 US disclosed
US-20250250294-A1 COMPOUND, METAL COMPLEX, OLEFIN POLYMERIZATION CATALYST COMPOSITION, OLEFIN POLYMERIZATION CATALYST, AND METHOD FOR PRODUCING OLEFIN-BASED POLYMER MITSUBISHI CHEMICAL CORPORATION (JP) 2025-08-07 US disclosed
EP-4596562-A1 COMPOUND, METAL COMPLEX, CATALYST COMPOSITION FOR OLEFIN POLYMERIZATION, CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER Mitsubishi Chemical Corporation (JP) 2025-08-06 EP disclosed
EP-1270554-A1 Sulfonyl urea derivatives and their use in the control of interleukin-1 activity PFIZER INC. (US) 2003-01-02 EP disclosed
EP-1270565-A1 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives PFIZER INC. (US) 2003-01-02 EP disclosed
US-6461822-B2 THERAPEUTIC TARGETS FOR AGENTS THAT SUPPRESS THE RELEASE OF INFLAMMATORY MEDIATORS SUCH AS INTERLEUKIN IL-1 AND IL-1 BETA PFIZER INC. 2002-10-08 US disclosed
US-6433009-B1 TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS PFIZER INC 2002-08-13 US disclosed
US-20020034764-A1 DIARYLSULFONYLUREA BINDING PROTEINS GABEL CHRISTOPHER A (US) 2002-03-21 US disclosed
US-6166064-A Sulfonyl urea derivatives and their use in the control of interleukin-1 activity PFIZER INC (US) 2000-12-26 US disclosed
EP-0987552-A2 Diarylsulfonylurea binding proteins Pfizer Products Inc. (US) 2000-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150291-A1 PROCESS FOR THE PREPARATION OF NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 ACHE 4208/4885MEN1 4568/4885KMT2A 3839/4885
US-20020034764-A1 DIARYLSULFONYLUREA BINDING PROTEINS HSPBP1, IL1B, IL1RN ACHE 4872/4885MEN1 4366/4885KMT2A 4456/4885
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators NLRP3, NLRP1, PYCARD ACHE 4848/4885MEN1 4299/4885KMT2A 3993/4885
US-20250388568-A1 NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 ACHE 4794/4885MEN1 3586/4885KMT2A 4514/4885
US-20220064125-A1 NOVEL PROCESSES NLRP3, NOD1, NLRP1 ACHE 4519/4885MEN1 4329/4885KMT2A 4832/4885
US-20250250294-A1 COMPOUND, METAL COMPLEX, OLEFIN POLYMERIZATION CATALYST COMPOSITION, OLEFIN POLYMERIZATION CATALYST, AND METHOD FOR PRODUCING OLEFIN-BASED POLYMER OSTC, PORCN, POF1B ACHE 2585/4885MEN1 1397/4885KMT2A 1852/4885
US-12466800-B2 N-((1,2,3,5,6,7-hexahydro-S-indacen-4-yl)carbamoyl)-4, 5, 6, 7-tetrahydrobenzofuran-2-sulfonamide derivatives and related compounds as NLPR3 modulators for the treatment of multiple sclerosis (MS) FFAR3, NLRP3, NOD1 ACHE 2420/4885MEN1 3405/4885KMT2A 4064/4885
US-11724988-B2 Processes NLRP3, NOD1, NLRP1 ACHE 3670/4885MEN1 3749/4885KMT2A 4604/4885
US-12459925-B2 Sulphonyl urea derivatives as NLRP3 inflammasome modulators NLRP3, NOD1, IL1B ACHE 4770/4885MEN1 2993/4885KMT2A 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.